Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This inhibition results in suppression of RA-FLS migration and invasion as well as decreased MMP-2 and MMP-9 expression.
|
31234900 |
2019 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression levels of RGS1, TLR3, vascular endothelial growth factor (VEGF), metalloproteinase-2 (MMP-2), MMP-9, and interleukin 1 receptor-associated kinase-4 (IRAK4) were determined.RGS1 was robustly increased in RA.
|
31012109 |
2019 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeted and MMP-2/9 responsive peptides for the treatment of rheumatoid arthritis.
|
31425817 |
2019 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased MMP-2 expression in relation to visfatin may represent a compensatory mechanism aimed at reducing cardiovascular risk in RA.
|
29475075 |
2018 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we use a probe that is activated by the key MMPs like MMP-2, -3, -9 and -13 and describe an imaging protocol for near infrared fluorescence OI of MMP activity in RA and control mice 6 days after disease induction as well as in mice with acute (1x challenge) and chronic (5x challenge) CHR on the right ear compared to healthy ears.
|
28518078 |
2017 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accordingly, the apelin-MMP-2 concentration relationship was reproduced in white (β (SE) = 0.367 (0.146), p = 0.01) but not black RA patients (β (SE) = 0.197 (0.220), p = 0.4), and only in those without (but not with) large erythrocyte sedimentation rates (β (SE) = 0.428 (0.143), p = 0.003) or interleukin-6 levels (β (SE) = 0.485 (0.288), p = 0.04).
|
28017911 |
2017 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the expression level of LOX in the synovial membranes was positively associated with the MVD and the expression levels of MMP‑2 and MMP‑9, suggesting that LOX promotes synovial hyperplasia and angiogenesis and that LOX may be a potential therapeutic target for rheumatoid arthritis.
|
28901438 |
2017 |
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, a weak association was found between MMP-2-1306 C/T polymorphism and RA (C vs. T, OR = 0.813, 95%CI = 0.694-0.953, p = 0.010) in overall populations.
|
26436849 |
2015 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Treatment of RA-FLS with GNF351 mitigated cytokine-mediated expression of matrix metalloproteinase-2 and -9 mRNA and diminished the RA-FLS invasive phenotype.
|
24309559 |
2014 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our observations suggest a synergetic effect of IL-17A and hypoxia that might contribute to the migration and invasion of RA-FLSs by upregulating the expression of MMP2 and MMP9 by activation of the NF-κB/HIF-1α pathway.
|
22960198 |
2013 |
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, logistic regression analyses revealed that the MMP-2 rs243865 C/T polymorphism was not associated with risk of RA.
|
24065540 |
2013 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the genes induced by IL-17A in RA synoviocytes, a molecular pattern of inflammation hypoxia-related genes, including CXC chemokine receptor 4 (CXCR4) and MMP2 was identified.
|
22532631 |
2012 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Gelatin zymography results showed EGCG inhibits IL-6/soluble IL-6R-induced matrix metalloproteinase-2 activity in RA synovial fibroblasts and in joint homogenates, possibly via up-regulation of sgp130 synthesis.
|
18796608 |
2008 |
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The MMP2 rs243865-T allele is not a major genetic factor for rheumatoid arthritis in the French Caucasian population.
|
18205826 |
2008 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-1beta increased the transcriptional and translational levels of MMP-1 and MMP-13 in rheumatoid arthritis FLSs, whereas the levels of MMP-2 and MMP-9 were unaffected.
|
17697361 |
2007 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis.
|
16872482 |
2006 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results of RT-PCR, Western blotting, and gelatinase zymography showed that His-DR was capable of inhibiting MMP-1 and MMP-2 secretion from NIT3T3 cells and RA synoviocytes stimulated by collagen II.
|
16967187 |
2006 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A significantly elevated secretion and activation of MMP-2 and MMP-9 were observed in RA FLS co-cultured with differentiated THP-1 cells or RA synovial monocytes/macrophages, compared with those co-cultured with undifferentiated THP-1 cells or healthy control peripheral blood monocytes.
|
16507143 |
2006 |
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These two alleles seemed to cooperate according to an additive model with respect to increased RA susceptibility (p = 0.004), and they were the low-expression alleles of the respective SNPs in a PLAT enhancer and the MMP2 promoter.
|
16356191 |
2006 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
There is major interest in designing inhibitors for matrix metalloproteinase 2 (MMP-2, gelatinase A) since this enzyme is known to be involved in pathological processes such as tumor invasion or rheumatoid arthritis.
|
15781326 |
2005 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2.
|
15248212 |
2004 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, although latent gelatinase A (MMP2) staining in PsA SM was equivalent to RA SM, increased gelatinase A activity was found in PsA SM over RA SM using zymography L82.4 (SD 62.8) vs 10.1 (SD 1.7); p = 0.02].
|
11824946 |
2002 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collagenase 3 mRNA is expressed simultaneously with MT1-MMP and gelatinase A mRNA in fibroblast-like cells of the synovial membrane in RA.
|
11959761 |
2002 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Given that MT1-MMP promotes matrix degradation by activating pro-MMP-2, these results suggest a novel mechanism whereby cytokine may contribute to articular destruction in rheumatoid arthritis (RA).
|
11678909 |
2001 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro, membrane-type matrix metalloproteinases (MT-MMP) are known to activate the zymogen of MMP-2 (proMMP-2, progelatinase A), which is one of the key MMP in joint destruction in rheumatoid arthritis.
|
10830778 |
2000 |